nVerses Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

nVerses Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-700	Closed	-$328K	–	1411
2024 Q2	$328K	Buy	+700	New	+$304K	0.2%	170

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

nVerses Capital's VRTX Position: Q3 2024 in Review

nVerses Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 700 shares — an estimated $328K sold.

nVerses Capital first reported a position in VRTX in Q2 2024 and held it in 1 quarter. The position peaked at $328K in Q2 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

nVerses Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 700 Vertex Pharmaceuticals shares in Q3 2024, an estimated $328K.
nVerses Capital first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 1 quarter.
nVerses Capital's Vertex Pharmaceuticals position peaked at $328K in Q2 2024.
1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.